Obesity
-
AMP is WAC — 04/10/26
Read more: AMP is WAC — 04/10/26Dam. What a few weeks. I Whistlered while I worked, but the avalanche of news has been hard to keep up with. (I mean, I found it funny.) If you’re interested, I’m hosting a free webinar on April 23 at 12 EST on Most Favored Nation. Quick 30-minute dive. Link to register is here: https://us06web.zoom.us/webinar/register/WN_iPlbMuS5RmeGSbcB8RSi-g…
-
340B, Affordable Care Act, Alzheimer’s, Biosimilars, Cell and Gene, CMMI, FDA, Inflation Reduction Act, Medicare Part D, ObesityAMP is WAC — 03/13/26
Read more: AMP is WAC — 03/13/26The Bigger They Are, the Faster They Grow. A new white paper from Health Capital Group, sponsored by Johnson & Johnson, analyzed HRSA’s OPAIS database from 2017 through 2023 and found something many observers of the 340B program have suspected for years; size is the dominant variable. Hospitals in the top quartile by bed size…
-
340B, Biosimilars, Caught my eye, DTC, Employers, FDA, Obesity, Reference Pricing, State-based Reform, ValueAMP is WAC — 2/20/26
Read more: AMP is WAC — 2/20/26We have some new folks around these parts so quick intro. I’m Jennifer Snow. I’ve spent 25 years inside the U.S. pharmaceutical policy world, not watching it from the outside, but sitting in the meetings, reading the rules, and translating what they actually mean for the people whose drugs are on the line. I’m not…
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Medicare Transaction Facilitator, Obesity, Reference PricingAMP is WAC — 1/9/26
Read more: AMP is WAC — 1/9/26Something is bugging me this week. Okay, lots of things are bugging me this week, but the one that is relevant to this newsletter is the STAT News headline that implied it is awesome to be a pharmaceutical executive in 2026. This week, there were reports of more than 25,000 layoffs in pharma last year.…
-
Affordable Care Act, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Obesity, Utilization ManagementBack at it
Read more: Back at itHo, Ho. Ho, Ho. It’s likely back to work you go. If you checked out the last week, here is what you might need to know before you get too far into your week. I will have the regular AMP is WAC on Friday but a catch-up felt in order. Waiting Game. The rollout of…
-
340B, Caught my eye, CMMI, Drug Prices, Medicaid, Medicare Negotiation, Medicare Part D, Obesity, Pharmacy Benefit ManagersAMP is WAC — 11/7/25
Read more: AMP is WAC — 11/7/25This week is such a kick in the pants with it getting dark so early. I’ve become like a cat chasing the daylight from room to room, ending my day on a swivel club chair that catches the very last rays of the setting sun. Have laptop, will travel. Shoe Drop. Late yesterday afternoon, the…
-
Biosimilars, Caught my eye, Generics, Health Equity, ICER, Medicare Advantage, Medicare Part D, Obesity, Pharmacy Benefit Managers, State-based Reform, Utilization Management, ValueAMP is WAC — 10/31/25
Read more: AMP is WAC — 10/31/25You won’t be surprised when I tell you that my favorite Halloween costume was when I wore a pair of scrubs with vinyl records attached (Spin Doctor). Yep. Right up there with Freudian slips. This year I will stick to my usual costume: the nice lady who hands out full-size bars to 200+ neighborhood kids.…
-
Biosimilars, Caught my eye, Drug Prices, Drug shortages, ICER, Inflation Reduction Act, Medicare Advantage, Medicare Part D, Obesity, Supply Chain, ValueCaught my eye — 4/11/25
Read more: Caught my eye — 4/11/25Some days I sit down the pottery wheel and I pull 4 bowls or vases in a row that are fantastic. Other days (like, oh, this Sunday and Wednesday) it all collapses. Here is hoping that all of us get better at staying centered and not collapsing. I’d Prefer Not. The 2026 Medicare Advantage and…
-
340B, Biosimilars, Caught my eye, CMMI, Medicare Advantage, Medicare Part D, Obesity, Pharmacy Benefit ManagersCaught my eye — 3/14/25
Read more: Caught my eye — 3/14/25With the exception of the ending of demos/models at the Centers for Medicare & Medicaid Innovation (CMMI), most of the news kind of rolled over me this week. So, instead, here is a capture of what is rattling around my chamber of health policy worries. Who’s on first? What’s on second? I don’t know ……
-
Caught my eye, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Obesity, ValueCaught my eye — 2/14/25
Read more: Caught my eye — 2/14/25Roses are red. Violets are blue. I love health policy, how about you? Public Health Gap: This week a poll found that a quarter of Americans see healthcare access and affordability as their top public health concern and think it would be best solved on the federal level. Among Democrats, 32% had it as their…
Latest news
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
- AMP is WAC — 03/20/26
- AMP is WAC — 03/13/26
Categories
- 340B (64)
- Affordable Care Act (23)
- Alzheimer's (11)
- Biosimilars (33)
- Caught my eye (102)
- Cell and Gene (8)
- Chevron Deference (2)
- CMMI (29)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (58)
- Drug shortages (15)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (13)
- Health Equity (4)
- Healthcare Costs (41)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (69)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (24)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (78)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (28)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (49)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (32)
- Supply Chain (8)
- Tariffs (2)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)